Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBIT Margin (2016 - 2025)

Historic EBIT Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 99.65%.

  • UroGen Pharma's EBIT Margin fell 300400.0% to 99.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 138.22%, marking a year-over-year decrease of 445200.0%. This contributed to the annual value of 107.06% for FY2024, which is 278300.0% down from last year.
  • Per UroGen Pharma's latest filing, its EBIT Margin stood at 99.65% for Q3 2025, which was down 300400.0% from 171.17% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EBIT Margin registered a high of 62.09% during Q4 2023, and its lowest value of 348.88% during Q1 2021.
  • Its 5-year average for EBIT Margin is 135.32%, with a median of 118.27% in 2024.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 83732600bps in 2021, then plummeted by -529000bps in 2025.
  • Over the past 5 years, UroGen Pharma's EBIT Margin (Quarter) stood at 123.13% in 2021, then grew by 9bps to 112.1% in 2022, then surged by 45bps to 62.09% in 2023, then crashed by -81bps to 112.59% in 2024, then grew by 11bps to 99.65% in 2025.
  • Its EBIT Margin was 99.65% in Q3 2025, compared to 171.17% in Q2 2025 and 182.26% in Q1 2025.